Pediatric Diabetes | 2019
Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes
Abstract
Results of genetic have led to off‐label glibenclamide treatment in patients with neonatal diabetes (NDM) because of potassium channel mutations. No pediatric form of glibenclamide was available. Glibenclamide was designated an orphan drug designation for NDM and a suspension was developed. As a part of the pediatric plan investigation, we assessed its acceptability, efficiency, and safety.